CD56, p53, and Cyclin D1 detection in plasma cells (PC) can help to predict prognosis of multiple myeloma (MM). Clinical and biochemical prognostic parameters were analysed in a group of 122 patients with primary diagnosed MM in the period 2011–2015. Bone marrow biopsies were analysed with Cyclin D1, p53, CD56 antibodies. Statistical analysis was performed using Microsoft Excel 2010 and Graph Pad Prism 5. Lack of CD56 expression and p53-positivity were significantly correlated with a low glomerular filtration rate (GFR), low platelet count and haemoglobin level, as well as with high serum creatinine levels. Patients with Cyclin D1 expression in PC had a significantly higher serum calcium level and more common osteolytic lesion in bones. CD56-negative as well as p53, Cyclin D1-positive groups had advanced Salmon–Durie MM stages by and significantly higher ß2-microglobulin. Expression of p53, Cyclin D1 and lack of CD56 antigen in PC are negative predictive factors in cases of MM, as these patients were diagnosed as having late Salmon–Durie stage and higher ß2-microglobulin level. Expression of p53 and lack of CD56 antigen in PC is associated with an increased creatinine level in blood and decreased GFR; therefore, these are criteria for chronic renal failure progression and poorer prognosis of MM.
There are about 2 billion people in the world who suffer from anaemia, mostly iron deficiency anaemia (IDA), by WHO data. Iron deficiency without anaemia is three times more common than IDA. In such patients, the condition of the small intestine should be evaluated, and malabsorption excluded. The aim of the study was to evaluate potential correlation between different types of enteropathy and iron absorption disturbances. The study was performed at the Latvian Maritime Medical Center “Gastroklinika” between the years 2014 and 2018. Iron absorption tests with 50 mg of oral iron gluconate were performed for each patient. Patients had filled in a FACIT questionnaire and had underwent video capsule endoscopy (VCE). A total of 48 patients were enrolled for analysis — 41 (85.4%) female and 7 (14.6%) male. Enteropathy was diagnosed in 35 cases: erosive — 17, erythematous — 12 and congestive — 6. By the time of VCE, 24 patients were suffering from anaemia. A total of 33 (68.7%) patients had problems with iron absorption, of whom 8 had no signs of enteropathy and 25 were diagnosed with enteropathy during VCE. IDA did not show a statistically significant correlation with enteropathy. However, the obtained results suggest that this should be studied further in association with small intestine malabsorption, to determine the precise role of enteropathy in IDA patients.
The relationship between HHV-6 and HHV-7 reactivation and development of post-autologous peripheral stem cell transplantation complications was examined. The presence of viral genomic sequences in whole peripheral blood and cell free plasma was determined by nested PCR, HHV-6 and HHV-7 load by real-time PCR, virus specific antibodies and cytokines in serum by ELISA, and HHV-6 variants by restriction endonuclease analysis. Clinical features, reactivation of viruses and serum TNF- α, and IL-6 concentrations were determined in seventy-six patients with Roseolovirus infection before and after transplantation. Anti-HHV-6 antibodies were found in 62 of 76 (81.6%) patients before transplantation. A significantly higher rate of single HHV-7 infection was found in patients with viral infection in comparison with single HHV-6 infection (p = 0.0003) and concurrent (HHV-6 and HHV-7) infection (p = 0.0017). Complications after transplantation developed in 30.3% of patients and reactivation of viruses was detected in all of these patients. Significant increase of HHV-6 and HHV-7 reactivation with simultaneous increase of pro-inflammatory cytokines serum levels suggests that both viruses may be involved in the development of complications after autologous peripheral blood stem cell transplantation via their immunomodulatory ability. The kinetics of the Roseolovirus reactivation may reflect the potential role of HHV-7 as a co-factor for HHV-6 activation.